Serina Therapeutics Announces Completion of Merger with AgeX Therapeutics
ALAMEDA, Calif., March 22, 2024 (GLOBE NEWSWIRE) -- AgeX Therapeutics, Inc. (AgeX; NYSE American: AGE), a biotechnology company developing therapeutics for human aging and regeneration, reported...
AgeX Therapeutics Reports Third Quarter 2023 Financial Results
If Juvenescence is as adept at extending the life spans of humans as it appears to be for biotechs, we might all live forever. AgeX Therapeutics, a biotech backed by the longevity specialist, continues to defy Father Time, ending yet another quarter with less than $1 million in the bank and repeating its well-worn going concern warning.
AgeX Therapeutics Reports Second Quarter 2023 Financial Results
AgeX Therapeutics Closes $36,000,000 Debt Exchange for Preferred Stock
AgeX Therapeutics Announces $36,000,000 Debt Exchange for Preferred Stock
ALAMEDA, Calif.--(BUSINESS WIRE)--AgeX Therapeutics, Inc. (“AgeX”; NYSE American: AGE), a biotechnology company developing therapeutics for human aging and regeneration, announced today that on May 17, 2023 it received a notice from the staff of the NYSE American (the “Exchange”) indicating that they intend to commence proceedings to delist AgeX common stock from the Exchange based upon AgeX’s non-compliance with the stockholders’ equity requirements set forth in Sections 1003(a)(i), (ii) and (iii) of the Exchange’s Company Guide by the end of a compliance plan period that expired on May 17, 2023. Specifically, AgeX does not meet the continued listing standards because it has stockholders equity of less than (A) $2,000,000 and has incurred losses from continuing operations and/or net losses during its two most recent fiscal years, (B) $4,000,000 and has incurred losses from continuing operations and/or net losses during three out of four of its most recent fiscal years, and (C) $6,000,000 or more and has reported losses from continuing operations and/or net losses in its five most recent fiscal years.
ALAMEDA, Calif.--(BUSINESS WIRE)--AgeX Therapeutics, Inc. (“AgeX”; NYSE American: AGE), a biotechnology company developing therapeutics for human aging and regeneration, reported its financial and operating results for quarter ended March 31, 2023.
AgeX Therapeutics Reports Fourth Quarter and Annual 2022 Financial Results